Abstract:Alzheimer′s disease (AD), the most common cause of dementia, represents one of the main clinical challenges of the century as the number of patients is predicted to triple by 2050. Despite the recent approval of three monoclonal antibodies targeting Amyloid β (Aβ) aggregates by the Food and Drug Administration (FDA), immunotherapies still face challenges due to the difficulty of antibodies crossing the blood-brain barrier (BBB). This necessitates administering large doses of drugs to achieve their therapeutic effects, which is associated with significant side effects. In this context, low-intensity focused ultrasound (LiFUS) appears as an innovative and non-invasive method which, in association with intravenous injection of microbubbles (MB), leads to a transient BBB opening. This innovative strategy has been extensively studied in different preclinical models and more recently in human clinical trials, particularly in the context of AD. LiFUS+MB seems to increase the inflammatory response at short term, but the time course of this response is not consistent between studies, certainly due to the discrepancy between LiFUS protocols used. Moreover, the impact at longer term is understudied and the mechanisms underlying this effect are still not well understood. In our study, we therefore used the TgF344-AD rat model of AD, to investigate the effect of a single or multiple exposures to LiFUS+MB in the entire brain, on inflammatory response and amyloid load. The ultrasound attenuation through the skull was corrected to apply a peak negative acoustic pressure of 450 kHz in all treated animals. Single LiFUS+MB exposure induces a slight astrocyte and microglial response 24 hours post-treatment whereas repeated LiFUS treatment seems to induce microglial reprogramming, leading to the adaptation of gene expression related to key functions such as inflammatory response, mitochondrial and energetic metabolism. In our rat model and LiFUS+MB protocol conditions, multiple exposures did not modulate soluble/poorly aggregated forms nor the highly aggregated forms of Aβ40 and Aβ42. For therapeutic AD management, LiFUS+MB could be combined with drugs such as immunotherapies. In a proof-of-concept experiment, we validated that LiFUS was also efficient to improve the brain entry of the anti-Aβ antibody, Aducanumab.

Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

P1‐017: 12/15‐lipoxygenase Inhibition Reverses Cognitive Impairment, Amyloidosis, TAU and Synaptic Pathology by Stimulating Autophagy in the Brain of Aged 3XTG Mice

Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice

Amyloid-β/Tau Burden and Neuroinflammation Dual-Targeted Nanomedicines Synergistically Restore Memory and Recognition of Alzheimer’s Disease Mice

FAAH Inhibition as a Path to Mitigate Alzheimer's Disease Progression in Mouse Models of Amyloidosis

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons

A Multi-Targeting Immunotherapy Ameliorates Multiple Facets of Alzheimer’ S Disease in 3xtg Mice

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease

Identification and drug-induced reversion of molecular signatures of Alzheimer’s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer’s Disease

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice

Treatment Combining Focused Ultrasound with Gastrodin Alleviates Memory Deficit and Neuropathology in an Alzheimer's Disease-Like Experimental Mouse Model

Repeated low-intensity focused ultrasound led to microglial profile changes at long term in TgF344-AD rats

Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil

Concurrent Transient Administration of Integrated Stress Response Inhibitors and BACE1 and/or BACE2 Activators as the Optimal Therapeutic Strategy for Alzheimer's Disease